Literature DB >> 18799048

Implication of the age in the clinical spectrum of giant cell arteritis.

M J Lopez-Diaz1, J Llorca, C Gonzalez-Juanatey, J L Peña-Sagredo, J Martin, M A Gonzalez-Gay.   

Abstract

OBJECTIVE: To assess the potential influence of the age in the clinical spectrum of giant cell arteritis (GCA).
METHODS: The case records of all patients diagnosed with biopsy-proven GCA at the Department of Medicine of the Hospital Xeral-Calde (Lugo, Northwest Spain) between 1981 and 2006 were reviewed.
RESULTS: During the period of study, 273 Lugo residents were diagnosed with biopsy-proven GCA. The mean age +/- standard deviation at the time of disease diagnosis was 75.1+/-6.8 years (median: 75 years; interquartile range 71-80 years). A longer delay to the diagnosis was observed in patients younger than 70 years of age (13.2+/-12.8 weeks) compared to those 70 years and older (9.4+/-10.2 weeks) (p=0.03). Patients younger than 70 years presented more frequently polymyalgia rheumatica (p=0.02), cerebrovascular accidents (p=0.004), peripheral arteriopathy of recent onset due to large artery stenosis (p=0.03) and high alkaline phosphatase values (p=0.001) than those 70 years and older. Individuals 70-79 years of age at the time of disease diagnosis had ESR values (90.2+/-22.8 mm/1st hour) lower than those observed in patients younger than 70 years (98.3+/-22.2 mm/1st hour) or 80 years and older (99.5+/-20.6 mm/1st hour) (p=0.005). However, no significant differences in the frequency of visual ischemic complications according to the age at the time of disease diagnosis were observed.
CONCLUSION: The results from this study display differences in the clinical spectrum of the disease according to the age of disease onset.

Entities:  

Mesh:

Year:  2008        PMID: 18799048

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

2.  Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.

Authors:  Hubert de Boysson; Maelle Le Besnerais; Félix Blaison; Aurélie Daumas; Pierre-André Jarrot; François Perrin; Nathalie Tieulié; Alexandre Maria; Pierre Duffau; Bruno Gombert; Maxime Samson; Olivier Espitia; Marc Lambert; Arsène Mékinian; Achille Aouba
Journal:  Arthritis Res Ther       Date:  2021-05-19       Impact factor: 5.156

Review 3.  Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis.

Authors:  James A Prior; Hoda Ranjbar; John Belcher; Sarah L Mackie; Toby Helliwell; Jennifer Liddle; Christian D Mallen
Journal:  BMC Med       Date:  2017-06-28       Impact factor: 8.775

4.  Giant cell arteritis: a multicenter observational study in Brazil.

Authors:  Alexandre Wagner Silva de Souza; Karine Yoshiye Kajiyama Okamoto; Fabiano Abrantes; Bruno Schau; Ana Beatriz Santos Bacchiega; Samuel Katsuyuki Shinjo
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.